Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Here's What Happened

Key Points

• Zealand Pharma A/S shares experienced a significant gap up, opening at $73.31 after previously closing at $69.00.
• Several analysts upgraded the stock's rating to "strong-buy", contributing to an average rating of "Strong Buy" among investment analysts.
• Despite a revenue of $1.43 billion, the company reported earnings per share of $16.06, missing expectations by $0.66.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $69.00, but opened at $73.31. Zealand Pharma A/S shares last traded at $73.31, with a volume of 130 shares.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. BNP Paribas raised shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Zacks Research upgraded shares of Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a research note on Monday, September 15th. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Five research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Strong Buy".

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.08 and a current ratio of 15.09. The company's 50 day moving average price is $61.27 and its 200 day moving average price is $65.50. The company has a market cap of $5.12 billion, a price-to-earnings ratio of 5.06 and a beta of 0.73.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. The firm had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. On average, equities research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.